Arena Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference

 Arena Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health
                               Care Conference

PR Newswire

SAN DIEGO, Feb. 27, 2013

SAN DIEGO, Feb. 27, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:
ARNA) announced today that the company is scheduled to present a corporate
overview at the Cowen and Company 33rd Annual Health Care Conference on
Wednesday, March 6, 2013, at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time),
at The Boston Marriott Copley Place in Boston, Massachusetts.

A live audio webcast of the presentation will be available under the investor
relations section of Arena's website at A replay of the
presentation will be available for 30 days following the event. Please connect
to Arena's website several minutes prior to the start of the webcast to ensure
adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering,
developing and commercializing novel drugs that target G protein-coupled
receptors to address major therapeutic areas, including cardiovascular,
central nervous system, inflammatory and metabolic diseases. BELVIQ^®
(lorcaserin HCl), Arena's internally discovered drug, was approved by the US
Food and Drug Administration in June 2012, and is under review for regulatory
approval in additional territories. Arena's US operations are located in San
Diego, California, and its operations outside of the United States, including
its commercial manufacturing facility, are located in Zofingen, Switzerland.
For more information, visit Arena's website at

Arena Pharmaceuticals^® and Arena^® are registered service marks of Arena
Pharmaceuticals, Inc. BELVIQ^® is a registered trademark of Arena
Pharmaceuticals GmbH.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that
involve a number of risks and uncertainties. Such forward-looking statements
include statements about the regulatory review of BELVIQ; and Arena's focus,
goals, strategy, research and development programs, and ability to discover
and develop compounds and commercialize drugs. For such statements, Arena
claims the protection of the Private Securities Litigation Reform Act of 1995.
Actual events or results may differ materially from Arena's expectations.
Factors that could cause actual results to differ materially from the
forward-looking statements include, but are not limited to, the following:
risks related to commercializing drugs, including regulatory, manufacturing
and supply issues and the pace of market acceptance; cash and revenues
generated from BELVIQ, including the impact of competition; the timing and
outcome of regulatory review is uncertain, and BELVIQ may not be approved for
marketing when expected or ever by any other regulatory agency; government and
commercial reimbursement and pricing decisions; risks related to relying on
collaborative arrangements; the timing and receipt of payments and fees, if
any, from collaborators; the entry into or modification or termination of
collaborative arrangements; unexpected or unfavorable new data; nonclinical
and clinical data is voluminous and detailed, and regulatory agencies may
interpret or weigh the importance of data differently and reach different
conclusions than Arena or others, request additional information, have
additional recommendations or change their guidance or requirements before or
after approval; data and other information related to any of Arena's research
and development may not meet safety, efficacy or other regulatory requirements
or otherwise be sufficient for further research and development, regulatory
review or approval or continued marketing; Arena's ability to obtain and
defend patents; the timing, success and cost of Arena's research and
development programs; results of clinical trials and other studies are subject
to different interpretations and may not be predictive of future results;
clinical trials and other studies may not proceed at the time or in the manner
expected or at all; having adequate funds; and satisfactory resolution of
litigation or other disagreements with others. Additional factors that could
cause actual results to differ materially from those stated or implied by
Arena's forward-looking statements are disclosed in Arena's filings with the
Securities and Exchange Commission. These forward-looking statements represent
Arena's judgment as of the time of this release. Arena disclaims any intent or
obligation to update these forward-looking statements, other than as may be
required under applicable law.

Contact: Arena Pharmaceuticals, Inc.     Media Contact: Russo Partners
Cindy McGee, Vice President,             David Schull, President
Investor Relations & Alliance Management                    858.717.2310
858.453.7200, ext. 1479

SOURCE Arena Pharmaceuticals, Inc.

Press spacebar to pause and continue. Press esc to stop.